Home > PJ (current issue) > News / News Centre | Search

PJ Online homeThe Pharmaceutical Journal
Vol 274 No 7341 p323
19 March 2005

This article
Reprint   Photocopy

  Acrobat Reader


News summary


Society included in review of health regulators

Review terms of reference

· To strengthen procedures for ensuring that the performance or conduct of non-medical health care professionals does not pose a threat to patient safety

· To ensure the operation of an effective system of continuing professional development and appraisal for non-medical health care staff

· To ensure the effective regulation of health care staff working in new roles

· To consider whether any changes are needed to the role, structure, function and number of regulators of non-medical health care professional staff

A review of all UK health regulators, including the Royal Pharmaceutical Society, was expected to be announced by the Department of Health after The Journal went to press.

The review follows the decision to examine the role, structure and function of the General Medical Council as a result of the findings of the Shipman Inquiry (PJ, 5 February, p137).

The central purpose of the review is to protect patient safety, said Andrew Foster, workforce director at the Department of Health.

Under the current system, he explained, health professionals are deemed to be competent and fit to practise when they first qualify, but there is no way of knowing whether this is still true 30 years later unless something goes wrong and disciplinary proceedings are taken.

Mr Foster commented that a more positive way that affirms fitness to practise on an occassional basis needs to be found. “What measures do we need,” he asked. “What role does the Government have in overseeing this and should we use a more co-ordinated approach?”

The review is expected to be completed before the end of the year and its findings will be used to inform the drafting of an Order under Section 60 of the Health Act 1999 to reform the regulation of pharmacists by the Royal Pharmaceutical Society.

Mr Foster said that the Order is to be used as “an enabling mechanism” rather than to set out definitive reforms.

The Society declined to comment until the review is announced.

Back to Top


©The Pharmaceutical Journal